Abstract: Niraparib (MK-4827) is a highly selective, orally bioavailable poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitor that has revolutionized the therapeutic landscape of advanced epithelial ovarian cancer. By exploiting the principle of synthetic lethality, niraparib induces cancer cell death, particularly in tumors harboring BRCA mutations or homologous recombination deficiency (HRD). Extensive clinical trials, including NOVA, PRIMA, and QUADRA, have demonstrated its profound efficacy in prolonging progression-free survival in both first-line maintenance and recurrent settings, leading to its global regulatory approval regardless of biomarker status. Despite its clinical success, niraparib is associated with significant hematological toxicities, such as thrombocytopenia and anemia, which necessitate careful monitoring and individualized dosing strategies. Current research is focused on overcoming resistance mechanisms and exploring synergistic combination therapies, particularly with immune checkpoint inhibitors and anti-angiogenic agents, to extend its clinical benefits to a broader patient population.
1. Introduction
Ovarian cancer remains one of the most lethal gynecological malignancies worldwide, with a high proportion of patients diagnosed at an advanced stage (FIGO stage III or IV) [2]. The standard primary treatment for advanced epithelial ovarian cancer involves cytoreductive debulking surgery followed by platinum-based chemotherapy [2]. While the majority of patients initially respond to this regimen, up to 80% experience disease recurrence within 12 to 18 months, highlighting a critical unmet need for effective maintenance therapies to prolong remission [4].
The advent of poly(ADP-ribose) polymerase (PARP) inhibitors has marked a paradigm shift in ovarian cancer management. Niraparib (trade name Zejula, developmentally known as MK-4827) is a potent PARP inhibitor that has received global approval from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [3]. Notably, niraparib was the first PARP inhibitor approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of their BRCA mutation or homologous recombination deficiency (HRD) status [1][3].
2. Pharmacological Activity
Niraparib is administered orally and exhibits favorable pharmacokinetic properties. It is rapidly absorbed, reaching maximum plasma concentration within 3 to 4 hours, and demonstrates an absolute bioavailability of approximately 73% [3][4]. Its absorption and metabolism are not significantly affected by food intake [3]. Niraparib has a large mean volume of distribution (1220 L) and a long terminal half-life ranging from 36 to over 57 hours, which supports a once-daily dosing regimen [3][4][11]. The drug is primarily metabolized in the liver via carboxylesterase-catalyzed amide hydrolysis into an inactive carboxylic acid metabolite (M1), which subsequently undergoes glucuronidation [3][4]. Preclinical models have also shown that niraparib can effectively cross the blood-brain barrier, demonstrating intracranial anti-tumor efficacy [1][3].
The clinical efficacy of niraparib has been established through several landmark phase III trials. The ENGOT-OV16/NOVA trial demonstrated that niraparib significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer. The median PFS was 21.0 months versus 5.5 months in the germline BRCA-mutated (gBRCAmut) cohort, 12.9 versus 3.8 months in the non-gBRCAmut HRD-positive cohort, and 9.3 versus 3.9 months in the overall non-gBRCAmut cohort compared to placebo [1][5][8]. The PRIMA/ENGOT-OV26 trial expanded its use to the first-line maintenance setting, showing a 57% reduction in the risk of disease progression or death in HRD-positive patients and a 38% reduction in the overall population [2][6]. Furthermore, the QUADRA trial confirmed its activity as a late-line treatment (≥3 prior lines) in heavily pretreated patients [6][8].
3. Molecular Mechanism of Action
Niraparib functions as a highly selective and potent inhibitor of the nuclear enzymes PARP-1 and PARP-2, with in vitro half-maximal inhibitory concentrations (IC50) of 3.8 nM and 2.1 nM, respectively [1][4][5]. PARP proteins play an essential role in detecting and repairing single-strand DNA breaks (SSBs) via the base excision repair (BER) pathway [7]. Niraparib competes with NAD+ at the catalytic domain of PARP, thereby blocking its catalytic activity and the formation of poly(ADP-ribose) polymers [7].
Beyond simple enzymatic inhibition, niraparib exerts its cytotoxic effects through "PARP trapping." It traps PARP-1 and PARP-2 complexes on damaged DNA, preventing DNA replication and transcription [4][7]. In normal cells, the resulting double-strand breaks (DSBs) are repaired by the error-free homologous recombination (HR) pathway. However, in cancer cells with HRD—such as those with BRCA1 or BRCA2 mutations—the cells are forced to rely on error-prone repair mechanisms like non-homologous end joining (NHEJ). This leads to massive genomic instability, cell cycle arrest, and apoptosis, a phenomenon known as "synthetic lethality" [1][5][7].
4. Structure-Activity Relationship (SAR)
Chemically, niraparib is 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide, with the molecular formula C19H20N4O and a molar mass of 320.4 g/mol [3][4]. The structural design of niraparib is critical to its high potency and selectivity. Early PARP inhibitors based on nicotinamide suffered from weak potency due to the free rotation of the amide bond. While other PARP inhibitors (such as olaparib and rucaparib) utilize an amide ring to restrain this rotation, niraparib overcomes the rotational flexibility by strategically positioning a hydrogen bond-accepting group. This allows the NH anti-carbonyl amide to form a stable intracellular hydrogen bond [4]. This unique conformational restraint contributes to niraparib's exceptional selectivity, making it greater than 500-fold more potent against PARP-1 and PARP-2 compared to other members of the PARP family [1][4].
5. Current Limitations
Despite its profound efficacy, the clinical utility of niraparib is constrained by its toxicity profile. Hematological adverse events are the most frequent and dose-limiting toxicities. In clinical trials, any-grade thrombocytopenia occurred in up to 61.3% of patients, with grade 3 or 4 thrombocytopenia affecting approximately 34% [3][9]. Anemia and neutropenia are also highly prevalent [9]. Non-hematological toxicities include gastrointestinal disturbances (nausea, vomiting, constipation) and fatigue [9]. Additionally, niraparib has been shown to inhibit dopamine, norepinephrine, and serotonin transporters, which can manifest clinically as cardiovascular effects, including hypertension, tachycardia, and hypertensive crises [4][11]. Rare but severe long-term risks include the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [3][5].
Another significant limitation is the development of acquired drug resistance. Cancer cells under therapeutic stress can develop secondary reversion mutations in BRCA1/2 that restore homologous recombination function, or they may upregulate drug efflux pumps, rendering the PARP inhibitor ineffective [7]. Furthermore, while niraparib is approved for all comers, patients with HR-proficient (HRp) tumors derive a numerically smaller progression-free survival benefit compared to those with HRD or BRCA mutations [1][2].
6. Future Perspectives
To mitigate the hematological toxicities associated with niraparib, clinical practice has shifted toward individualized dosing. The NORA and PRIMA trials demonstrated that an individualized starting dose—reducing the dose from 300 mg to 200 mg daily for patients with a baseline body weight <77 kg or platelet count <150,000/μL—significantly lowers the incidence of adverse events and discontinuation rates without compromising therapeutic efficacy [8][9].
Future research is heavily focused on combination therapies to overcome resistance and enhance efficacy, particularly in HR-proficient populations. Preclinical and translational evidence suggests that PARP inhibitors can modulate the tumor microenvironment, increasing genomic instability and upregulating PD-L1 expression, thereby providing a strong rationale for combining niraparib with immune checkpoint inhibitors (ICIs) [10]. Trials such as TOPACIO are currently evaluating the combination of niraparib with pembrolizumab [8]. Additionally, combining niraparib with anti-angiogenic agents like bevacizumab (as seen in the AVANOVA trial) has shown promising improvements in progression-free survival compared to niraparib alone [8][11]. These synergistic approaches represent the next frontier in maximizing the clinical utility of niraparib in ovarian cancer.
